Streptococcus pneumoniae uses its surface protein PspA to sequester and neutralize the antimicrobial peptide indolicidin, revealing a broader immune evasion strategy beyond its known defense against lactoferricins.
Broad AMP shield confirmedPspA protects pneumococcus not just from lactoferricins but also from the structurally unrelated AMP indolicidin, suggesting broad-spectrum antimicrobial peptide evasion
What the researchers found
PspA-negative pneumococci were significantly more sensitive to indolicidin-induced killing, and mass spectrometry confirmed direct PspA-indolicidin binding, demonstrating that PspA provides broad-spectrum protection against cationic antimicrobial peptides.
Why it matters
Understanding how bacteria evade our natural antimicrobial defenses is crucial for developing effective vaccines and peptide-based antibiotics. PspA's role as a broad AMP shield — not just specific to lactoferricins — makes it an even more attractive vaccine target.
The numbers in context
PspA-negative pneumococci showed significantly greater sensitivity to indolicidin-induced killing compared to PspA-positive bacteria.
How the study worked
Researchers compared indolicidin susceptibility between PspA-expressing and PspA-negative S. pneumoniae strains using killing assays. Chemical removal of choline-binding proteins, capsule-negative mutants, anti-PspA antibodies, and soluble PspA competition were tested. Direct binding was confirmed by mass spectrometry.
Who was studied
Streptococcus pneumoniae bacterial strains
What this study cannot tell us
In vitro killing assays don't capture the full complexity of lung or blood infections. Only one AMP (indolicidin) was tested beyond lactoferricins — the breadth of PspA's protective effect across all human AMPs is unknown. Strain-specific differences in PspA could affect generalizability.
How to read the evidence
Preliminary evidence from well-designed in vitro experiments with multiple confirmatory approaches (genetic knockouts, antibody blocking, competitive inhibition, mass spectrometry binding confirmation).
When this study was published
Published in 2024, building on established PspA research with new findings about broader antimicrobial peptide evasion.
The bigger picture
Antimicrobial peptides are being developed as alternatives to conventional antibiotics. But if bacteria like pneumococcus can neutralize them using surface proteins, we need to account for these evasion mechanisms. PspA vaccines could strip away this defense, making pneumococcus vulnerable to both the body's natural AMPs and therapeutic peptide antibiotics.
Questions still open
- Does PspA protect against other human antimicrobial peptides beyond indolicidin and lactoferricins?
- Could combining PspA-targeting antibodies with therapeutic AMPs create a synergistic treatment for pneumococcal infections?
- Do other respiratory pathogens use similar surface protein shields against antimicrobial peptides?
Common questions
How does PspA protect bacteria from antimicrobial peptides?
Could this research lead to better pneumonia treatments?
Read the original research
Pneumococcal surface protein A (PspA) prevents killing of Streptococcus pneumoniae by indolicidin.
Scientific reports, 14(1), 23517
Citation
Waz, Natalha T; Milani, Barbara; Assoni, Lucas; Coelho, Guilherme Rabelo; Sciani, Juliana M; Parisotto, Thaís; Ferraz, Lucio F C; Hakansson, Anders P; Converso, Thiago R; Darrieux, Michelle. (2024). Pneumococcal surface protein A (PspA) prevents killing of Streptococcus pneumoniae by indolicidin.. Scientific reports, 14(1), 23517. https://doi.org/10.1038/s41598-024-73564-9